<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>PAPAVERINE HYDROCHLORIDE - papaverine hydrochloride injection, solution </strong><br>American Regent, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1><span class="Bold">PAPAVERINE HYDROCHLORIDE INJECTION, USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>This product is to be used by or under the direction of a physician.</p>
<p>Each vial contains a sufficient amount to permit withdrawal and administration of the volume specified on the label.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">Papaverine Hydrochloride, USP, is the hydrochloride of an alkaloid obtained from opium or prepared synthetically. It belongs to the benzylisoquinoline group of alkaloids. It does not contain a phenanthrene group as do morphine and codeine.</p>
<p>Papaverine Hydrochloride, USP, is 6,7-dimethoxy-1- veratrylisoquinoline hydrochloride and contains, on the dried basis, not less than 98.5% of C<span class="Sub">20</span>H<span class="Sub">21</span>NO<span class="Sub">4</span>•HCI. The molecular weight is 375.85. The structural formula is as shown.</p>
<div class="Figure"><img alt="Adobe Systems" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e&amp;name=5ee8d0b3-figure-01.jpg"></div>
<p>Papaverine Hydrochloride occurs as white crystals or white crystalline powder. One gram dissolves in about 30 mL of water and in 120 mL of alcohol. It is soluble in chloroform and practically insoluble in ether.</p>
<p>Papaverine Hydrochloride Injection, USP, is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow solution.</p>
<p>Papaverine Hydrochloride, for parenteral administration, is a smooth-muscle relaxant that is available in vials containing 30 mg/mL. Each vial also contains edetate disodium 0.005%. The 10 mL vials also contain chlorobutanol 0.5% as a preservative. pH may be adjusted with sodium citrate and/or citric acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">The most characteristic effect of papaverine is relaxation of the tonus of all smooth muscle, especially when it has been spasmodically contracted. Papaverine Hydrochloride apparently acts directly on the muscle itself. This relaxation is noted in the <span class="Italics">vascular system </span>and <span class="Italics">bronchial musculature </span>and in the <span class="Italics">gastrointestinal, biliary </span>and <span class="Italics">urinary tracts</span>.</p>
<p>The main actions of papaverine are exerted on cardiac and smooth muscle. Papaverine relaxes various smooth muscles, especially those of larger arteries; this relaxation may be prominent if spasm exists. The antispasmodic effect is a direct one and unrelated to muscle innervation, and the muscle still responds to drugs and other stimuli causing contraction.  Papaverine has minimal actions on the central nervous system, although very large doses tend to produce some sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> in some patients. In certain circumstances, mild respiratory stimulation can be observed, but this is therapeutically inconsequential. Papaverine stimulates respiration by acting on carotid and aortic body chemoreceptors.</p>
<p>Papaverine relaxes the smooth musculature of the larger blood vessels, including the coronary, cerebral, peripheral, and pulmonary arteries. This action is particularly evident when such vessels are in spasm, induced reflexly or by drugs, and it provides the basis for the clinical use of papaverine in peripheral or pulmonary arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>.</p>
<p>Experimentally in dogs, the alkaloid has been shown to cause fairly marked and long-lasting coronary <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and an increase in coronary blood flow. However, it also appears to have a direct inotropic effect and, when increased mechanical activity coincides with decreased systemic pressure, increases in coronary blood flow may not be sufficient to prevent brief periods of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxic</span> myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>Papaverine is effective by all routes of administration. A considerable fraction of the drug localizes in fat deposits and in the liver, with the remainder being distributed throughout the body. It is metabolized in the liver. About 90% of the drug is bound to plasma protein. Although estimates of its biologic half-life vary widely, reasonably constant plasma levels can be maintained with oral administration at 6 hour intervals. The drug is excreted in the urine in an inactive form.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as <span class="Italics">vascular spasm </span>associated with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="316995" conceptname="Coronary occlusion">coronary occlusion</span>), <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, peripheral and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> in which there is a vasospastic element, or certain cerebral angiospastic states; and <span class="Italics">visceral spasm, </span>as in ureteral, biliary, or gastrointestinal <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Intravenous injection of papaverine is contraindicated in the presence of complete atrioventricular <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. When conduction is depressed, the drug may produce transient ectopic rhythms of ventricular origin, either <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span> or paroxysmal <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p>Papaverine Hydrochloride is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> by intracorporeal injection. The intracorporeal injection of papaverine hydrochloride has been reported to have resulted in persistent <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> requiring medical and <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold Italics">General
</span></h2>
<p class="First">Papaverine Hydrochloride Injection, USP, should not be added to Lactated Ringer’s Injection, because precipitation would result.</p>
<p>Papaverine Hydrochloride should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. The medication should be discontinued if hepatic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> becomes evident or if liver function test values become altered.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold Italics">Pregnancy
</span></h2>
<p class="First"><span class="Bold Italics">Pregnancy Category C - </span>No teratogenic effects were observed in rats when papaverine hydrochloride was administered subcutaneously as a single agent. It is not known whether papaverine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Papaverine Hydrochloride should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.3"></a><p></p>
<h2><span class="Bold Italics">Nursing Mothers
</span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when papaverine hydrochloride is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.4"></a><p></p>
<h2><span class="Bold Italics">Pediatric Use
</span></h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The following side effects have been reported: <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">general discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, intensive <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the face, perspiration, increase in the depth of respiration, increase in heart rate, a slight <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, and excessive sedation.</p>
<p><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, probably related to an immune mechanism, has been reported infrequently. Rarely, this has progressed to cirrhosis.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug dependence</span> resulting from the abuse of many of the selective depressants, including papaverine hydrochloride, has been reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<div class="Section">
<a name="section-9.1"></a><p></p>
<h2><span class="Bold Italics">Signs and Symptoms – 
</span></h2>
<p class="First">The symptoms of toxicity from papaverine hydrochloride often result from vasomotor instability and include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>. In large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, papaverine is a potent inhibitor of cellular respiration and a weak calcium antagonist. Following an oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 15 g, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> with <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> have been reported. No information on toxic serum concentrations is available.</p>
<p>Following intravenous overdosing in animals, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> have been reported.  The oral median lethal dose in rats is 360 mg/kg.</p>
</div>
<div class="Section">
<a name="section-9.2"></a><p></p>
<h2><span class="Bold Italics">Treatment – 
</span></h2>
<p class="First">To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics Underline">Physician’s Desk Reference</span> (PDR). In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient.</p>
<p>Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor vital signs, blood gases, blood chemistry values, and other variables.</p>
<p>If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occur, consider diazepam, phenytoin, or phenobarbital. If the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are refractory, general anesthesia with thiopental or halothane and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> with a neuromuscular blocking agent may be necessary.</p>
<p>For <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, consider intravenous fluids, elevation of the legs, and an inotropic vasopressor, such as dopamine or norepinephrine (levarterenol). Theoretically, calcium gluconate may be helpful in treating some of the toxic cardiovascular effects of papaverine; monitor the ECG and plasma calcium concentrations.</p>
<p>Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of papaverine hydrochloride.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">Papaverine Hydrochloride may be administered intravenously or intramuscularly. The intravenous route is recommended when an immediate effect is desired, but the drug <span class="Italics">must </span>be injected <span class="Italics">slowly </span>over the course of 1 or 2 minutes to avoid uncomfortable or alarming side effects.</p>
<p>Parenteral administration of papaverine hydrochloride in doses of 1 to 4 mL is repeated every 3 hours as indicated. In the treatment of cardiac <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, 2 doses may be given 10 minutes apart.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Papaverine Hydrochloride Injection, USP, 30 mg/mL</p>
<p>0517-4002-25              2 mL Vial                                packaged in boxes of 25<br>0517-4010-01              10 mL Multiple Dose Vial*    packaged individually</p>
<p>*The 10 mL Multiple Dose Vial contains chlorobutanol 0.5% as a preservative.</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).</p>
<p><span class="Bold">PROTECT FROM LIGHT. </span>RETAIN IN CARTON UNTIL TIME OF USE.</p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><span class="Bold"><br></span><span class="Bold">SHIRLEY, NY 11967</span></p>
<p>IN4002<br>Rev. 1/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First">PRINCIPAL DISPLAY PANEL – 2 mL Carton</p>
<p><span class="Bold">PAPAVERINE</span><span class="Bold"><br></span><span class="Bold">HYDROCHLORIDE</span><br>INJECTION, USP</p>
<p><span class="Bold">60 mg/2 mL</span> (30 mg/mL)</p>
<p><span class="Bold">NDC 0517-4002-25</span></p>
<p><span class="Bold">25 X 2 mL VIALS</span></p>
<p><span class="Bold">FOR SINGLE USE ONLY</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Each mL contains: Papaverine Hydrochloride 30 mg, Edetate Disodium 0.005% and Water for Injection q.s.  pH may be adjusted with Sodium Citrate and/or Citric Acid. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). <span class="Bold">PROTECT FROM LIGHT.</span></p>
<p>RETAIN IN CARTON UNTIL TIME OF USE.</p>
<p>Directions For Use: See Package Insert.</p>
<p><span class="Bold">AMERICAN </span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><br>SHIRLEY, NY 11967</p>
<p>Rev. 1/10</p>
<div class="Figure"><img alt="5ee8d0b3-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e&amp;name=5ee8d0b3-figure-02.jpg"></div>
<p>PRINCIPAL DISPLAY PANEL – 10 mL Carton</p>
<p><span class="Bold">NDC 0517-4010-01</span></p>
<p><span class="Bold">10 mL</span> MULTIPLE DOSE VIAL</p>
<p><span class="Bold">PAPAVERINE</span><span class="Bold"><br></span><span class="Bold">HYDROCHLORIDE</span><br>INJECTION, USP</p>
<p><span class="Bold">300 mg/10 mL</span><span class="Bold"><br></span>(30 mg/mL)</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">AMERICAN </span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span></p>
<p>SHIRLEY, NY 11967</p>
<p>Rev. 1/10</p>
<div class="Figure"><img alt="5ee8d0b3-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e&amp;name=5ee8d0b3-figure-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PAPAVERINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">papaverine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-4010</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PAPAVERINE HYDROCHLORIDE</strong> (PAPAVERINE) </td>
<td class="formItem">PAPAVERINE HYDROCHLORIDE</td>
<td class="formItem">30 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLOROBUTANOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-4010-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">09/01/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PAPAVERINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">papaverine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-4002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PAPAVERINE HYDROCHLORIDE</strong> (PAPAVERINE) </td>
<td class="formItem">PAPAVERINE HYDROCHLORIDE</td>
<td class="formItem">30 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-4002-25</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">09/01/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5ee8d0b3-841f-45a7-a363-76363ad481c1</div>
<div>Set id: 9e5e2ce4-7a57-4c61-a826-64c8d11d038e</div>
<div>Version: 1</div>
<div>Effective Time: 20110824</div>
</div>
</div> <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
